logo
Plus   Neg
Share
Email

Novartis: FDA, EMA To Review Filings For Ofatumumab - Quick Facts

Novartis (NVS) announced the US FDA and European Medicines Agency have accepted the company's Supplemental Biologics License Application (sBLA) and Marketing Authorization Application for ofatumumab, a B-cell therapy, for the treatment of relapsing forms of multiple sclerosis in adults. The company expects regulatory approval for ofatumumab in the US in June 2020 and in Europe by the second quarter of 2021.

Novartis noted that, if approved, ofatumumab has the potential to become a first-choice treatment for a broad RMS population and the first B-cell therapy that is easy to start and manage in a monthly subcutaneous injection that can be self-administered at home using an autoinjector pen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered.
Follow RTT
>